Please note that the ITEA Office will be closed from 25 December 2024 to 1 January 2025 inclusive.
SIGNET
Sensing and Image-Guided Neurological therapies, cardiac Electrophysiology and Tumour treatments
Project description
The overall objective of SIGNET is to develop efficient image-guided treatment workflows to replace currently complex procedures in cardiology, oncology and neurology. We develop systems and technologies, AI-enabled products and solutions, necessary to ultimately realize the North Star of single-episode, personalized, dose-adaptive, high-precision Magnetic Resonance guided treatments and interventions. These technologies and solutions aim to improve patient comfort, safety, treatment outcome, staff availability and economic viability. We focus on use cases where alternative image guidance approaches are either not feasible or where the value of direct MR visualization is obvious.
https://signetproject.com/
Project leader
Canada
Imeka
Canada
Modus Medical Devices Inc.
Canada
Spain
Adas3D Medical SL
Spain
Galgo Medical, SL
Spain
The Netherlands
Academic Medical Centre Amsterdam (AMC)
The Netherlands
Brain Science Tools BV
The Netherlands
Braincarta BV
The Netherlands
LifeTec Group BV
The Netherlands
Machnet Medical Robotics BV
The Netherlands
Philips Electronics Nederland BV Electronics Nederland B.V.
The Netherlands
Philips Medical Systems Nederland BV
The Netherlands
UMC Utrecht
The Netherlands
United States
Imricor Medical Systems, Inc.
United States
Project publications
- SIGNET Project profile leaflet Project Leaflet 20 March 2023 Download
- By and for end-users Magazine article Issue 42 (July 2022) Download
- ITEA PO Days 2024 - Project poster SIGNET Project poster 11 September 2024
Work package documents
- SIGNET SotA.docx Work package deliverable document 12 December 2023
- SIGNET_D6.1-Dissemination and Standardization Plan-Final.pdf Work package deliverable document 17 June 2022